Immunic, Inc. (IMUX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.9600 |
| Open | 3.9800 |
| Bid | 3.7000 x 800 |
| Ask | 4.9200 x 800 |
| Day's Range | 3.8220 - 4.0650 |
| 52 Week Range | 2.5200 - 14.5000 |
| Volume | |
| Avg. Volume | 793,587 |
| Market Cap | 103.423M |
| Beta (5Y Monthly) | 1.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.8820 |
| Earnings Date | Feb 24, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Immunic to Participate in Industry and Scientific Conferences in July
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following industry and scientific conferences in July:
- PR Newswire
Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that data from its phase 2 EMPhASIS trial of lead asset, vidofludimus calcium (IMU-838), in patients with relapsing-remitting multiple sclerosis (RRMS), has been published in the peer reviewed journal, Annals of Clinical and Translational Neurology.
- PR Newswire
Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, industry and investor conferences in June:
